Answers are grounded in this paper and cite their sources.
Myotonic Dystrophy Type 1 (DM1) is an autosomal dominant, repeat expansion, progressive multisystem disorder. While central nervous system (CNS) involvement has been well established, a consensus on a dedicated protocol to assess cognitive function and collect CNS biomarkers is still lacking in this disease. In the era of disease-modifying therapies that cross the blood-brain barrier (BBB), availability of mechanistically relevant neuropsychological probes and reliable biomarkers of DM1 pathology is no longer deferrable. Consequently, to better define and harmonize a CNS assessment pathway, the Myotonic Dystrophy Clinical Research Network (DMCRN) convened a workshop entitled ‘‘Myotonic Dystrophy CNS Workshop’’ in September 2024. Presenters described the protean manifestations of CNS involvement in DM1, shared data about neuropsychological assessments available with cross-fertilization from other neurological and neurodegenerative diseases and discussed existing data and future perspectives on CNS radiological biomarkers.
No takes yet. Share an insight, caveat, or question.
Aggradi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: